Status:
RECRUITING
Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome
Lead Sponsor:
Asociación para Evitar la Ceguera en México
Conditions:
Retinopathy of Prematurity
Eligibility:
All Genders
1-12 years
Phase:
PHASE2
PHASE3
Brief Summary
Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppress...
Eligibility Criteria
Inclusion
- Retinopathy of prematurity stages III, IV and V in which we can not treat with laser o cryotherAPY
Exclusion
- PATIENTS THAT COULD BE TREATED WITH CRYOTHERAPY OR LASER
Key Trial Info
Start Date :
July 1 2007
Trial Type :
INTERVENTIONAL
End Date :
November 1 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00346814
Start Date
July 1 2007
End Date
November 1 2024
Last Update
July 31 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asociación para Evitar la Ceguera en México Hospital "Luis Sanchez Bulnes"
Mexico City, Mexico DF, Mexico, 04030